Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen

Belite Bio (NASDAQ:BLTE) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

BLTE has been the topic of a number of other reports. Maxim Group set a $200.00 price objective on shares of Belite Bio in a research note on Tuesday, December 2nd. HC Wainwright raised their price objective on shares of Belite Bio from $185.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday. Cantor Fitzgerald lifted their target price on Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a research report on Tuesday. Benchmark reiterated a “buy” rating on shares of Belite Bio in a report on Tuesday. Finally, Morgan Stanley increased their price target on Belite Bio from $191.00 to $201.00 and gave the stock an “overweight” rating in a research report on Tuesday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Belite Bio presently has a consensus rating of “Moderate Buy” and an average price target of $202.33.

Belite Bio Trading Up 0.4%

BLTE stock opened at $173.30 on Friday. The company’s 50-day moving average price is $170.11 and its 200 day moving average price is $124.77. Belite Bio has a 52 week low of $49.00 and a 52 week high of $200.00. The company has a market cap of $6.50 billion, a P/E ratio of -75.35 and a beta of -1.46.

Belite Bio (NASDAQ:BLTE) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.18. On average, equities research analysts expect that Belite Bio will post -1.17 earnings per share for the current year.

Hedge Funds Weigh In On Belite Bio

Several institutional investors have recently bought and sold shares of BLTE. Caitong International Asset Management Co. Ltd grew its holdings in shares of Belite Bio by 28,200.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after purchasing an additional 282 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Belite Bio by 28.1% in the third quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock valued at $87,000 after purchasing an additional 257 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Belite Bio in the 4th quarter worth approximately $103,000. Persistent Asset Partners Ltd acquired a new position in Belite Bio during the 4th quarter worth $108,000. Finally, GAMMA Investing LLC lifted its holdings in Belite Bio by 11.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock worth $130,000 after buying an additional 176 shares in the last quarter. Institutional investors own 0.53% of the company’s stock.

Key Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Cantor Fitzgerald published a bullish outlook that analysts say supports upside potential for BLTE shares; this contributed to positive investor sentiment today. Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says
• Positive Sentiment: Morgan Stanley is also cited as forecasting strong price appreciation for Belite Bio, helping lift the stock as momentum and analyst optimism draw buyer interest. Morgan Stanley Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Positive Sentiment: An American Banking News item highlights HC Wainwright’s continued bullish stance (Buy, $200 target), which can limit downside even as estimates shift. HC Wainwright Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock
• Neutral Sentiment: Reported short‑interest figures appear to show zero shares and a 0.0 days‑to‑cover ratio — likely a data anomaly or reporting issue rather than meaningful new short activity. That makes the short‑interest data neutral for near‑term price direction.
• Negative Sentiment: HC Wainwright reduced its near‑term EPS forecasts in a March 3 research note: Q1 2026 EPS cut from ($0.56) to ($0.71), Q2 from ($0.56) to ($0.72), Q3 from ($0.57) to ($0.73), Q4 2026 from $5.80 to $4.05, and FY2026 from $4.12 to $1.89. Although the firm kept a Buy rating and $200 target, the sizable downward revisions to quarterly and full‑year earnings increase uncertainty around near‑term results and could pressure the stock if upcoming operational or clinical updates fall short. Belite Bio (BLTE) MarketBeat company page

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.